MYD88 and neoplasm: It has been reported that F. nucleatum can regulate TLR4-mediated pathway activation and MYD88-induced autophagy in tumor cells to cause a weak response to 5-Fu, capecitabine, and oxaliplatin [14], therefore providing a guideline for clinicians to select appropriate therapy for F. nucleatum-positive CRC patients.